DREAM On: Cell Cycle Control in Development and Disease

Literature Cited

1. 1. 

   Abbassi R, Johns TG, Kassiou M, Munoz L. 2015. DYRK1A in neurodegeneration and cancer: molecular basis and clinical implications. Pharmacol. Ther. 151:87–98
   [Google Scholar]
2. 2. 

   Adayev T, Wegiel J, Hwang Y-W. 2011. Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A). Arch. Biochem. Biophys. 507:212–18
   [Google Scholar]
3. 3. 

   Allegra CJ, Aberle DR, Ganschow P, Hahn SM, Lee CN et al. 2010. National Institutes of Health State-of-the-Science Conference statement: diagnosis and management of ductal carcinoma in situ September 22–24, 2009. J. Natl. Cancer Inst. 102:161–69
   [Google Scholar]
4. 4. 

   Andrejka L, Wen H, Ashton J, Grant M, Iori K et al. 2011. Animal-specific C-terminal domain links myeloblastosis oncoprotein (Myb) to an ancient repressor complex. PNAS 108:17438–43
   [Google Scholar]
5. 5. 

   Aranda S, Laguna A, de la Luna S. 2011. DYRK family of protein kinases: evolutionary relationships, biochemical properties, and functional roles. FASEB J 25:449–62
   [Google Scholar]
6. 6. 

   Bainor AJ, Saini S, Calderon A, Casado-Polanco R, Giner-Ramirez B et al. 2018. The HDAC-associated Sin3B protein represses DREAM complex targets and cooperates with APC/C to promote quiescence. Cell Rep 25:2797–807.e8
   [Google Scholar]
7. 7. 

   Beall EL, Bell M, Georlette D, Botchan MR 2004. Dm-myb mutant lethality in Drosophila is dependent upon mip130: positive and negative regulation of DNA replication. Genes Dev 18:1667–80
   [Google Scholar]
8. 8. 

   Beall EL, Manak JR, Zhou S, Bell M, Lipsick JS, Botchan MR. 2002. Role for a Drosophila Myb-containing protein complex in site-specific DNA replication. Nature 420:833–37
   [Google Scholar]
9. 9. 

   Becker W. 2018. A wake-up call to quiescent cancer cells—potential use of DYRK1B inhibitors in cancer therapy. FEBS J 285:1203–11
   [Google Scholar]
10. 10. 

    Becker W, Weber Y, Wetzel K, Eirmbter K, Tejedor FJ, Joost H-G. 1998. Sequence characteristics, subcellular localization, and substrate specificity of DYRK-related kinases, a novel family of dual specificity protein kinases. J. Biol. Chem. 273:25893–902
    [Google Scholar]
11. 11. 

    Beshiri ML, Holmes KB, Richter WF, Hess S, Islam ABMMK et al. 2012. Coordinated repression of cell cycle genes by KDM5A and E2F4 during differentiation. PNAS 109:18499–504
    [Google Scholar]
12. 12. 

    Boichuk S, Parry JA, Makielski KR, Litovchick L, Baron JL et al. 2013. The DREAM complex mediates GIST cell quiescence and is a novel therapeutic target to enhance imatinib-induced apoptosis. Cancer Res 73:5120–29
    [Google Scholar]
13. 13. 

    Boxem M, van den Heuvel S. 2002. C. elegans class B synthetic multivulva genes act in G₁ regulation. Curr. Biol. 12:906–11
    [Google Scholar]
14. 14. 

    Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T. 1998. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 391:597–601
    [Google Scholar]
15. 15. 

    Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. 2006. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat. Genet. 38:1043–48
    [Google Scholar]
16. 16. 

    Ceol CJ, Horvitz HR. 2001. dpl-1 DP and efl-1 E2F act with lin-35 Rb to antagonize Ras signaling in C. elegans vulval development. Mol. Cell 7:461–73
    [Google Scholar]
17. 17. 

    Chen J-Y, Lin J-R, Tsai F-C, Meyer T 2013. Dosage of Dyrk1a shifts cells within a p21-cyclin D1 signaling map to control the decision to enter the cell cycle. Mol. Cell 52:87–100
    [Google Scholar]
18. 18. 

    Chen X, Müller GA, Quaas M, Fischer M, Han N et al. 2013. The forkhead transcription factor FOXM1 controls cell cycle-dependent gene expression through an atypical chromatin binding mechanism. Mol. Cell. Biol. 33:227–36
    [Google Scholar]
19. 19. 

    Classon M, Harlow E. 2002. The retinoblastoma tumour suppressor in development and cancer. Nat. Rev. Cancer 2:910–17
    [Google Scholar]
20. 20. 

    Classon M, Salama S, Gorka C, Mulloy R, Braun P, Harlow E. 2000. Combinatorial roles for pRB, p107, and p130 in E2F-mediated cell cycle control. PNAS 97:10820–25
    [Google Scholar]
21. 21. 

    Cobrinik D, Lee MH, Hannon G, Mulligan G, Bronson RT et al. 1996. Shared role of the pRB-related p130 and p107 proteins in limb development. Genes Dev 10:1633–44
    [Google Scholar]
22. 22. 

    Dannenberg J-H, van Rossum A, Schuijff L, te Riele H. 2000. Ablation of the retinoblastoma gene family deregulates G₁ control causing immortalization and increased cell turnover under growth-restricting conditions. Genes Dev 14:3051–64
    [Google Scholar]
23. 23. 

    DeCaprio JA. 2009. How the Rb tumor suppressor structure and function was revealed by the study of Adenovirus and SV40. Virology 384:274–84
    [Google Scholar]
24. 24. 

    DeCaprio JA. 2014. Human papillomavirus type 16 E7 perturbs DREAM to promote cellular proliferation and mitotic gene expression. Oncogene 33:4036–38
    [Google Scholar]
25. 25. 

    DeCaprio JA, Duensing A. 2014. The DREAM complex in antitumor activity of imatinib mesylate in gastrointestinal stromal tumors. Curr. Opin. Oncol. 26:415–21
    [Google Scholar]
26. 26. 

    DeGregori J. 2002. The genetics of the E2F family of transcription factors: shared functions and unique roles. Biochim. Biophys. Acta Rev. Cancer 1602:131–50
    [Google Scholar]
27. 27. 

    Dick FA, Goodrich DW, Sage J, Dyson NJ 2018. Non-canonical functions of the RB protein in cancer. Nat. Rev. Cancer 18:442–51
    [Google Scholar]
28. 28. 

    Dimova DK, Dyson NJ. 2005. The E2F transcriptional network: old acquaintances with new faces. Oncogene 24:2810–26
    [Google Scholar]
29. 29. 

    Down CF, Millour J, Lam EW-F, Watson RJ. 2012. Binding of FoxM1 to G2/M gene promoters is dependent upon B-Myb. Biochim. Biophys. Acta Gene Regul. Mech. 1819:855–62
    [Google Scholar]
30. 30. 

    Duchon A, Herault Y. 2016. DYRK1A, a dosage-sensitive gene involved in neurodevelopmental disorders, is a target for drug development in Down syndrome. Front. Behav. Neurosci. 10:104
    [Google Scholar]
31. 31. 

    Dynlacht BD, Brook A, Dembski M, Yenush L, Dyson N 1994. DNA-binding and trans-activation properties of Drosophila E2F and DP proteins. PNAS 91:6359–63
    [Google Scholar]
32. 32. 

    Dyson N. 1998. The regulation of E2F by pRB-family proteins. Genes Dev 12:2245–62
    [Google Scholar]
33. 33. 

    Dyson NJ. 2016. RB1: a prototype tumor suppressor and an enigma. Genes Dev 30:1492–502
    [Google Scholar]
34. 34. 

    Engeland K. 2018. Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM. Cell Death Differ 25:114–32
    [Google Scholar]
35. 35. 

    Ewton DZ, Hu J, Vilenchik M, Deng X, Luk K-c et al. 2011. Inactivation of Mirk/dyrk1b kinase targets quiescent pancreatic cancer cells. Mol. Cancer Ther. 10:2104–14
    [Google Scholar]
36. 36. 

    Fay DS, Han M. 2000. The synthetic multivulval genes of C. elegans: functional redundancy, Ras-antagonism, and cell fate determination. Genesis 26:279–84
    [Google Scholar]
37. 37. 

    Fischer M, Grossmann P, Padi M, DeCaprio JA 2016. Integration of TP53, DREAM, MMB-FOXM1 and RB-E2F target gene analyses identifies cell cycle gene regulatory networks. Nucleic Acids Res 44:6070–86
    [Google Scholar]
38. 38. 

    Fischer M, Grundke I, Sohr S, Quaas M, Hoffmann S et al. 2013. p53 and cell cycle dependent transcription of kinesin family member 23 (KIF23) is controlled via a CHR promoter element bound by DREAM and MMB complexes. PLOS ONE 8:e63187
    [Google Scholar]
39. 39. 

    Fischer M, Quaas M, Steiner L, Engeland K. 2016. The p53-p21-DREAM-CDE/CHR pathway regulates G₂/M cell cycle genes. Nucleic Acids Res 44:164–74
    [Google Scholar]
40. 40. 

    Florens L, Washburn MP. 2006. Proteomic analysis by multidimensional protein identification technology. Methods Mol. Biol. 328:159–75
    [Google Scholar]
41. 41. 

    Forristal C, Henley SA, MacDonald JI, Bush JR, Ort C et al. 2014. Loss of the mammalian DREAM complex deregulates chondrocyte proliferation. Mol. Cell. Biol. 34:2221–34
    [Google Scholar]
42. 42. 

    Friedman E. 2013. Mirk/dyrk1B kinase in ovarian cancer. Int. J. Mol. Sci. 14:5560–75
    [Google Scholar]
43. 43. 

    Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM et al. 1986. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323:643–46
    [Google Scholar]
44. 44. 

    Gagrica S, Hauser S, Kolfschoten I, Osterloh L, Agami R, Gaubatz S 2004. Inhibition of oncogenic transformation by mammalian Lin-9, a pRB-associated protein. EMBO J 23:4627–38
    [Google Scholar]
45. 45. 

    Georlette D, Ahn S, MacAlpine DM, Cheung E, Lewis PW et al. 2007. Genomic profiling and expression studies reveal both positive and negative activities for the Drosophila Myb–MuvB/dREAM complex in proliferating cells. Genes Dev 21:2880–96
    [Google Scholar]
46. 46. 

    Goetsch PD, Garrigues JM, Strome S. 2017. Loss of the Caenorhabditis elegans pocket protein LIN-35 reveals MuvB's innate function as the repressor of DREAM target genes. PLOS Genet 13:e1007088
    [Google Scholar]
47. 47. 

    Gordon RR, Nelson PS. 2012. Cellular senescence and cancer chemotherapy resistance. Drug Resist. Updat. 15:123–31
    [Google Scholar]
48. 48. 

    Guiley KZ, Iness AN, Saini S, Tripathi S, Lipsick JS et al. 2018. Structural mechanism of Myb–MuvB assembly. PNAS 115:10016–21
    [Google Scholar]
49. 49. 

    Guiley KZ, Liban TJ, Felthousen JG, Ramanan P, Litovchick L, Rubin SM 2015. Structural mechanisms of DREAM complex assembly and regulation. Genes Dev 29:961–74
    [Google Scholar]
50. 50. 

    Harrison MM, Ceol CJ, Lu X, Horvitz HR 2006. Some C. elegans class B synthetic multivulva proteins encode a conserved LIN-35 Rb-containing complex distinct from a NuRD-like complex. PNAS 103:16782–87
    [Google Scholar]
51. 51. 

    Hiebert SW, Chellappan SP, Horowitz JM, Nevins JR. 1992. The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes Dev 6:177–85
    [Google Scholar]
52. 52. 

    Himpel S, Tegge W, Frank R, Leder S, Joost HG, Becker W. 2000. Specificity determinants of substrate recognition by the protein kinase DYRK1A. J. Biol. Chem. 275:2431–38
    [Google Scholar]
53. 53. 

    Hu J, Deng H, Friedman EA. 2013. Ovarian cancer cells, not normal cells, are damaged by Mirk/Dyrk1B kinase inhibition. Int. J. Cancer 132:2258–69
    [Google Scholar]
54. 54. 

    Iness AN, Felthousen J, Ananthapadmanabhan V, Sesay F, Saini S et al. 2019. The cell cycle regulatory DREAM complex is disrupted by high expression of oncogenic B-Myb. Oncogene 38:1080–92
    [Google Scholar]
55. 55. 

    Iness AN, Litovchick L. 2018. MuvB: a key to cell cycle control in ovarian cancer. Front. Oncol. 8:223
    [Google Scholar]
56. 56. 

    Iness AN, Rubinsak L, Meas SJ, Chaoul J, Sayeed S 2021. Oncogenic B-Myb is associated with deregulation of the DREAM-mediated cell cycle gene expression program in high grade serous ovarian carcinoma clinical tumor samples. Front. Oncol. 11:637193
    [Google Scholar]
57. 57. 

    James CD, Saini S, Sesay F, Ko K, Felthousen-Rusbasan J et al. 2021. Restoring the DREAM complex inhibits the proliferation of high-risk HPV positive human cells. Cancers 13:489
    [Google Scholar]
58. 58. 

    Joaquin M, Bessa M, Saville MK, Watson RJ. 2002. B-Myb overcomes a p107-mediated cell proliferation block by interacting with an N-terminal domain of p107. Oncogene 21:7923–32
    [Google Scholar]
59. 59. 

    Kerkhoff E, Fedorov LM, Siefken R, Walter AO, Papadopoulos T, Rapp UR 2000. Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein. Cell Growth Differ 11:185–90
    [Google Scholar]
60. 60. 

    Kim H, Lee KS, Kim AK, Choi M, Choi K et al. 2016. A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition. Dis. Model. Mech. 9:839–48
    [Google Scholar]
61. 61. 

    Kim MJ, Cervantes C, Jung Y-S, Zhang X, Zhang J et al. 2021. PAF remodels the DREAM complex to bypass cell quiescence and promote lung tumorigenesis. Mol. Cell 81:81698–714.e6
    [Google Scholar]
62. 62. 

    Kittler R, Pelletier L, Heninger AK, Slabicki M, Theis M et al. 2007. Genome-scale RNAi profiling of cell division in human tissue culture cells. Nat. Cell Biol. 9:1401–12
    [Google Scholar]
63. 63. 

    Kleinschmidt MA, Wagner TU, Liedtke D, Spahr S, Samans B, Gaubatz S. 2009. lin9 is required for mitosis and cell survival during early zebrafish development. J. Biol. Chem. 284:13119–27
    [Google Scholar]
64. 64. 

    Knight AS, Notaridou M, Watson RJ. 2009. A Lin-9 complex is recruited by B-Myb to activate transcription of G₂/M genes in undifferentiated embryonal carcinoma cells. Oncogene 28:1737–47
    [Google Scholar]
65. 65. 

    Kobayashi K, Suzuki T, Iwata E, Nakamichi N, Suzuki T et al. 2015. Transcriptional repression by MYB3R proteins regulates plant organ growth. EMBO J 34:1992–2007
    [Google Scholar]
66. 66. 

    Korenjak M, Taylor-Harding B, Binne UK, Satterlee JS, Stevaux O et al. 2004. Native E2F/RBF complexes contain Myb-interacting proteins and repress transcription of developmentally controlled E2F target genes. Cell 119:181–93
    [Google Scholar]
67. 67. 

    Laoukili J, Kooistra MRH, Brás A, Kauw J, Kerkhoven RM et al. 2005. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat. Cell Biol. 7:126–36
    [Google Scholar]
68. 68. 

    Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EY. 1987. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 235:1394–99
    [Google Scholar]
69. 69. 

    Lewis PW, Beall EL, Fleischer TC, Georlette D, Link AJ, Botchan MR. 2004. Identification of a Drosophila Myb-E2F2/RBF transcriptional repressor complex. Genes Dev 18:2929–40
    [Google Scholar]
70. 70. 

    Li X, Wang W, Wang J, Malovannaya A, Xi Y et al. 2015. Proteomic analyses reveal distinct chromatin-associated and soluble transcription factor complexes. Mol. Syst. Biol. 11:775
    [Google Scholar]
71. 71. 

    Liban TJ, Medina EM, Tripathi S, Sengupta S, Henry RW et al. 2017. Conservation and divergence of C-terminal domain structure in the retinoblastoma protein family. PNAS 114:4942–47
    [Google Scholar]
72. 72. 

    Liban TJ, Thwaites MJ, Dick FA, Rubin SM 2016. Structural conservation and E2F binding specificity within the retinoblastoma pocket protein family. J. Mol. Biol. 428:3960–71
    [Google Scholar]
73. 73. 

    Litovchick L, Chestukhin A, DeCaprio JA 2004. Glycogen synthase kinase 3 phosphorylates RBL2/p130 during quiescence. Mol. Cell. Biol. 24:8970–80
    [Google Scholar]
74. 74. 

    Litovchick L, Florens LA, Swanson SK, Washburn MP, DeCaprio JA. 2011. DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly. Genes Dev 25:801–13
    [Google Scholar]
75. 75. 

    Litovchick L, Sadasivam S, Florens L, Zhu X, Swanson SK et al. 2007. Evolutionarily conserved multisubunit RBL2/p130 and E2F4 protein complex represses human cell cycle-dependent genes in quiescence. Mol. Cell 26:539–51
    [Google Scholar]
76. 76. 

    MacDonald J, Ramos-Valdes Y, Perampalam P, Litovchick L, DiMattia GE, Dick FA. 2017. A systematic analysis of negative growth control implicates the DREAM complex in cancer cell dormancy. Mol. Cancer Res. 15:371–81
    [Google Scholar]
77. 77. 

    MacPherson D. 2008. Insights from mouse models into human retinoblastoma. Cell Div 3:9
    [Google Scholar]
78. 78. 

    Mages CFS, Wintsche A, Bernhart SH, Müller GA 2017. The DREAM complex through its subunit Lin37 cooperates with Rb to initiate quiescence. eLife 6:e26876
    [Google Scholar]
79. 79. 

    Malumbres M, Barbacid M. 2001. To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer 1:222–31
    [Google Scholar]
80. 80. 

    Mannefeld M, Klassen E, Gaubatz S. 2009. B-MYB is required for recovery from the DNA damage–induced G₂ checkpoint in p53 mutant cells. Cancer Res 69:4073–80
    [Google Scholar]
81. 81. 

    Marceau AH, Felthousen JG, Goetsch PD, Iness AN, Lee H-W et al. 2016. Structural basis for LIN54 recognition of CHR elements in cell cycle-regulated promoters. Nat. Commun. 7:12301
    [Google Scholar]
82. 82. 

    Marescal O, Cheeseman IM. 2020. Cellular mechanisms and regulation of quiescence. Dev. Cell 55:259–71
    [Google Scholar]
83. 83. 

    Matsuo T, Kuramoto H, Kumazaki T, Mitsui Y, Takahashi T. 2012. LIN54 harboring a mutation in CHC domain is localized to the cytoplasm and inhibits cell cycle progression. Cell Cycle 11:3227–36
    [Google Scholar]
84. 84. 

    Mauro LJ, Seibel MI, Diep CH, Spartz A, Perez Kerkvliet C et al. 2021. Progesterone receptors promote quiescence and ovarian cancer cell phenotypes via DREAM in p53-mutant fallopian tube models. J. Clin. Endocrinol. Metab. 106:71929–55
    [Google Scholar]
85. 85. 

    Menon VR, Ananthapadmanabhan V, Swanson S, Saini S, Sesay F et al. 2019. DYRK1A regulates the recruitment of 53BP1 to the sites of DNA damage in part through interaction with RNF169. Cell Cycle 18:531–51
    [Google Scholar]
86. 86. 

    Müller GA, Engeland K. 2010. The central role of CDE/CHR promoter elements in the regulation of cell cycle-dependent gene transcription. FEBS J 277:877–93
    [Google Scholar]
87. 87. 

    Müller GA, Quaas M, Schümann M, Krause E, Padi M et al. 2012. The CHR promoter element controls cell cycle–dependent gene transcription and binds the DREAM and MMB complexes. Nucleic Acids Res 40:1561–78
    [Google Scholar]
88. 88. 

    Müller GA, Wintsche A, Stangner K, Prohaska SJ, Stadler PF, Engeland K. 2014. The CHR site: definition and genome-wide identification of a cell cycle transcriptional element. Nucleic Acids Res 42:10331–50
    [Google Scholar]
89. 89. 

    Ning Y-Q, Liu N, Lan K-K, Su Y-N, Li L et al. 2020. DREAM complex suppresses DNA methylation maintenance genes and precludes DNA hypermethylation. Nat. Plants 6:942–56
    [Google Scholar]
90. 90. 

    Nor Rashid N, Yusof R, Watson RJ 2011. Disruption of repressive p130–DREAM complexes by human papillomavirus 16 E6/E7 oncoproteins is required for cell-cycle progression in cervical cancer cells. J. Gen. Virol. 92:2620–27
    [Google Scholar]
91. 91. 

    Odajima J, Saini S, Jung P, Ndassa-Colday Y, Ficaro S et al. 2016. Proteomic landscape of tissue-specific cyclin E functions in vivo. PLOS Genet 12:e1006429
    [Google Scholar]
92. 92. 

    Ogawa Y, Nonaka Y, Goto T, Ohnishi E, Hiramatsu T et al. 2010. Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A. Nat. Commun. 1:86
    [Google Scholar]
93. 93. 

    Osterloh L, von Eyss B, Schmit F, Rein L, Hübner D et al. 2007. The human synMuv-like protein LIN-9 is required for transcription of G2/M genes and for entry into mitosis. EMBO J 26:144–57
    [Google Scholar]
94. 94. 

    Pardee AB. 1989. G1 events and regulation of cell proliferation. Science 246:603–8
    [Google Scholar]
95. 95. 

    Patel AJ, Wan YW, Al-Ouran R, Revelli JP, Cardenas MF et al. 2019. Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors. PNAS 116:21715–26
    [Google Scholar]
96. 96. 

    Pattschull G, Walz S, Gründl M, Schwab M, Rühl E et al. 2019. The Myb-MuvB complex is required for YAP-dependent transcription of mitotic genes. Cell Rep 27:3533–46.e7
    [Google Scholar]
97. 97. 

    Perampalam P, Hassan HM, Lilly GE, Passos DT, Torchia J et al. 2021. Disrupting the DREAM transcriptional repressor complex induces apolipoprotein overexpression and systemic amyloidosis in mice. J. Clin. Invest. 131:e140903
    [Google Scholar]
98. 98. 

    Pilkinton M, Sandoval R, Colamonici OR. 2007. Mammalian Mip/LIN-9 interacts with either the p107, p130/E2F4 repressor complex or B-Myb in a cell cycle-phase-dependent context distinct from the Drosophila dREAM complex. Oncogene 26:7535–43
    [Google Scholar]
99. 99. 

    Quaas M, Müller GA, Engeland K. 2012. p53 can repress transcription of cell cycle genes through a p21^WAF1/CIP1-dependent switch from MMB to DREAM protein complex binding at CHR promoter elements. Cell Cycle 11:4661–72
    [Google Scholar]
100. 100. 

     Rayman JB, Takahashi Y, Indjeian VB, Dannenberg J-H, Catchpole S et al. 2002. E2F mediates cell cycle-dependent transcriptional repression in vivo by recruitment of an HDAC1/mSin3B corepressor complex. Genes Dev 16:933–47
     [Google Scholar]
101. 101. 

     Reichert N, Wurster S, Ulrich T, Schmitt K, Hauser S et al. 2010. Lin9, a subunit of the mammalian DREAM complex, is essential for embryonic development, for survival of adult mice, and for tumor suppression. Mol. Cell. Biol. 30:2896–908
     [Google Scholar]
102. 102. 

     Roberts MS, Sahni JM, Schrock MS, Piemonte KM, Weber-Bonk KL et al. 2020. LIN9 and NEK2 are core regulators of mitotic fidelity that can be therapeutically targeted to overcome taxane resistance. Cancer Res 80:1693–706
     [Google Scholar]
103. 103. 

     Rubin SM, Gall A-L, Zheng N, Pavletich NP 2005. Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylation-induced E2F release. Cell 123:1093–106
     [Google Scholar]
104. 104. 

     Rubin SM, Sage J, Skotheim JM 2020. Integrating old and new paradigms of G1/S control. Mol. Cell 80:183–92
     [Google Scholar]
105. 105. 

     Sadasivam S, Duan S, DeCaprio JA 2012. The MuvB complex sequentially recruits B-Myb and FoxM1 to promote mitotic gene expression. Genes Dev 26:474–89
     [Google Scholar]
106. 106. 

     Sage J, Mulligan GJ, Attardi LD, Miller A, Chen S et al. 2000. Targeted disruption of the three Rb-related genes leads to loss of G₁ control and immortalization. Genes Dev 14:3037–50
     [Google Scholar]
107. 107. 

     Sahni JM, Gayle SS, Webb BM, Weber-Bonk KL, Seachrist DD et al. 2017. Mitotic vulnerability in triple-negative breast cancer associated with LIN9 is targetable with BET inhibitors. Cancer Res 77:5395–408
     [Google Scholar]
108. 108. 

     Sala A, De Luca A, Giordano A, Peschle C 1996. The retinoblastoma family member p107 binds to B-MYB and suppresses its autoregulatory activity. J. Biol. Chem. 271:28738–40
     [Google Scholar]
109. 109. 

     Sandoval R, Pilkinton M, Colamonici OR 2009. Deletion of the p107/p130-binding domain of Mip130/LIN-9 bypasses the requirement for CDK4 activity for the dissociation of Mip130/LIN-9 from p107/p130-E2F4 complex. Exp. Cell Res. 315:2914–20
     [Google Scholar]
110. 110. 

     Sanidas I, Morris R, Fella KA, Rumde PH, Boukhali M et al. 2019. A code of mono-phosphorylation modulates the function of RB. Mol. Cell 73:985–1000.e6
     [Google Scholar]
111. 111. 

     Schade AE, Oser MG, Nicholson HE, DeCaprio JA. 2019. Cyclin D–CDK4 relieves cooperative repression of proliferation and cell cycle gene expression by DREAM and RB. Oncogene 38:4962–76
     [Google Scholar]
112. 112. 

     Schmit F, Cremer S, Gaubatz S. 2009. LIN54 is an essential core subunit of the DREAM/LINC complex that binds to the cdc2 promoter in a sequence-specific manner. FEBS J 276:5703–16
     [Google Scholar]
113. 113. 

     Schmit F, Korenjak M, Mannefeld M, Schmitt K, Franke C et al. 2007. LINC, a human complex that is related to pRB-containing complexes in invertebrates regulates the expression of G₂/M genes. Cell Cycle 6:1903–13
     [Google Scholar]
114. 114. 

     Shin H, Reiner DJ. 2018. The signaling network controlling C. elegans vulval cell fate patterning. J. Dev. Biol. 6:30
     [Google Scholar]
115. 115. 

     Simmons AR, Davies KA, Wang W, Liu Z, Bergmann DC 2019. SOL1 and SOL2 regulate fate transition and cell divisions in the Arabidopsis stomatal lineage. Development 146:3dev171066
     [Google Scholar]
116. 116. 

     Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL et al. 2013. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J. Natl. Cancer Inst. 105:701–10
     [Google Scholar]
117. 117. 

     Stiegler P, Kasten M, Giordano A. 1998. The RB family of cell cycle regulatory factors. J. Cell Biochem. Suppl.30–31–30–36
     [Google Scholar]
118. 118. 

     Tabuchi TM, Deplancke B, Osato N, Zhu LJ, Barrasa MI et al. 2011. Chromosome-biased binding and gene regulation by the Caenorhabditis elegans DRM complex. PLOS Genet 7:e1002074
     [Google Scholar]
119. 119. 

     Tanaka Y, Patestos NP, Maekawa T, Ishii S 1999. B-myb is required for inner cell mass formation at an early stage of development. J. Biol. Chem. 274:28067–70
     [Google Scholar]
120. 120. 

     Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P et al. 2017. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. J. Exp. Clin. Cancer Res. 36:63
     [Google Scholar]
121. 121. 

     Trimarchi JM, Lees JA. 2002. Sibling rivalry in the E2F family. Nat. Rev. Mol. Cell Biol. 3:11–20
     [Google Scholar]
122. 122. 

     Uxa S, Bernhart SH, Mages CFS, Fischer M, Kohler R et al. 2019. DREAM and RB cooperate to induce gene repression and cell-cycle arrest in response to p53 activation. Nucleic Acids Res 47:9087–103
     [Google Scholar]
123. 123. 

     van den Heuvel S, Dyson NJ. 2008. Conserved functions of the pRB and E2F families. Nat. Rev. Mol. Cell Biol. 9:713–24
     [Google Scholar]
124. 124. 

     Viens LJ, Henley SJ, Watson M, Markowitz LE, Thomas CC et al. 2016. Human papillomavirus-associated cancers—United States, 2008–2012. Morb. Mortal. Wkly. Rep. 65:661–66
     [Google Scholar]
125. 125. 

     Vorster PJ, Goetsch P, Wijeratne TU, Guiley KZ, Andrejka L et al. 2020. A long lost key opens an ancient lock: Drosophila Myb causes a synthetic multivulval phenotype in nematodes. Biol. Open 9:bio051508
     [Google Scholar]
126. 126. 

     Wang W, Sijacic P, Xu P, Lian H, Liu Z. 2018. Arabidopsis TSO1 and MYB3R1 form a regulatory module to coordinate cell proliferation with differentiation in shoot and root. PNAS 115:13E3045–54
     [Google Scholar]
127. 127. 

     Wang Y, Wen L, Zhao SH, Ai Z, Guo JZ, Liu WC. 2013. FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients. Lung Cancer 79:173–79
     [Google Scholar]
128. 128. 

     Wen H, Andrejka L, Ashton J, Karess R, Lipsick JS 2008. Epigenetic regulation of gene expression by Drosophila Myb and E2F2-RBF via the Myb-MuvB/dREAM complex. Genes Dev 22:601–14
     [Google Scholar]
129. 129. 

     Wikenheiser-Brokamp KA. 2004. Rb family proteins differentially regulate distinct cell lineages during epithelial development. Development 131:4299–310
     [Google Scholar]
130. 130. 

     Yu P, Huang B, Shen M, Lau C, Chan E et al. 2001. p15^PAF, a novel PCNA associated factor with increased expression in tumor tissues. Oncogene 20:484–89
     [Google Scholar]
131. 131. 

     Zhang X, Cheng L, Minn K, Madan R, Godwin AK et al. 2014. Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells. Oncotarget 5:11365–80
     [Google Scholar]
132. 132. 

     Zluhan-Martínez E, Pérez-Koldenkova V, Ponce-Castañeda MV, Sánchez MP, García-Ponce B et al. 2020. Beyond what your retina can see: similarities of retinoblastoma function between plants and animals, from developmental processes to epigenetic regulation. Int. J. Mol. Sci. 21:4925
     [Google Scholar]
133. 133. 

     zur Hausen H. 2009. Papillomaviruses in the causation of human cancers—a brief historical account. Virology 384:260–65
     [Google Scholar]